Company
LON:ONC
Oncimmune Holdings PLC is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The company has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
139 stories · page 4 of 7
“Oncimmune has been in discussion for some months now to utilise its differentiated technical knowledge to develop a comprehensive diagnostic tool capable of characterising the immune system's response to COVID-19 and, as a consequence, bei
"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” said chief executive, Dr Adam Hill
Academics looked at the deployment of the EarlyCDT Lung test in combination with computed tomography
The programme will see the deployment of the biomarker discovery engine, SeroTag
EarlyCDT Lung enables earlier and accurate diagnosis of lung cancer in high-risk patients that could mean an intervention is offered early
The latest data was taken from a successful large-scale trial
The Early detection of Cancer of the Lung Scotland (ECLS) trial was delivered by the Universities of Dundee and St Andrews with NHS Tayside, and co-funded by Oncimmune, the Scottish Chief Scientist Office and the Scottish Government
"Our ongoing relationship with Roche is providing us with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling,” said chief executive, Dr Adam Hill
The firm's ImmunoINSIGHTS team was integral to a paper published in the journal ‘Arthritis Research & Therapy’
The country's Agência Nacional de Vigilância Sanitária gave the green light to the EarlyCDT Lung blood test
The City broker's forecasts are unchanged, while it has reiterated its 150p share price target
Oncimmune was upbeat about its prospects after it confirmed revenues in the fiscal year just ended would be in line with the market's expectations
The contract involves a substantial upfront payment said the AIM-listed group and starts immediately
Archive
Banquet Buffet Oncimmune 100p £63.5m (AIM:ONC) The global immunodiagnostics group today announces that it has signed a foothill contract to utilise the Company's Early CDT Lung panel...
The latest agreement is one of a series of deals inked in the last two months that showed the “full breadth” of the firm’s commercial offering, said chief executive Adam Hill
The presentation will be the first time that the clinical utility of autoantibodies has been presented at the American Society of Clinical Oncology conference
Archive
Oncimmune Holdings 87.5p £55.56m (AIM:ONC) The global immunodiagnostics group, today announces it has signed an antigen targeting collaboration to support drug development with a leading US biopharmaceutical company which is developing nove
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The UK group will support its new partner with antigen targeting using its biomarker discovery engine, SeroTag
Frontier IP Group (LON:FIPP) 65p £32.9m Frontier IP, a specialist in commercialising intellectual property, has raised its equity stake in portfolio company Celerum Limited from 10 per cent to 33.8 per cent.
